PARIS, Oct 12 (Reuters) - Sanofi SASY.PA will invest 170 million euros ($202 million) to expand its vaccines manufacturing site at Val-de-Reuil in north-western France, in a drive aimed at boosting the production of one of its influenza vaccines.
The French drugmaker said on Thursday that the new facility would allow its Sanofi Pasteur vaccines division to expand the supply of the VaxigripTetra product to up to 70 countries. Production at the new facility will start from 2022 onwards.
"Influenza continues be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals," said David Loew, executive vice president at Sanofi and head of Sanofi Pasteur.
"As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge," he added.
Annual influenza epidemics result in three to five million cases of severe illness worldwide and 250,000-500,000 deaths, according to the World Health Organisation (WHO).
VaxigripTetra, which is currently available in 20 European countries, works as a "quadrivalent" vaccine that protects against four strains of the virus also known as flu.
Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline GSK.L and CSL's (CSL) Seqirus, which includes the old Novartis NOVN.S flu vaccine business.
($1 = 0.8430 euros)
Sanofi invests 170 million euros in French vaccines facility
Before making any financial decisions based on what you read, always consult an advisor or expert.
The aim of HotCopper News is to report and comment on news in the financial and investment markets. HotCopper provides no advice on dealing in securities and is not a financial advisor. Professional advice should be sought before making any investment decisions.
Contact editor: [email protected]